Bromelain protects against cisplatin-induced ocular toxicity through mitigating oxidative stress and inflammation
Ferah Okkay, Irmak, Okkay, Ufuk, Bayram, Cemil, Cicek, Betul, Sezen, Selma, Aydin, Ismail Cagri, Mendil, Ali Sefa, Hacimuftuoglu, Ahmet
The aim of this study was to investigate the molecular, biochemical, and histopathological effects of bromelain, which has antioxidant and anti-inflammatory properties, against cisplatin-induced ocular toxicity. The groups were designed as (1) Control, (2) Cisplatin (7 mg/kg, intraperitoneally), (3) Cisplatin + Bromelain (50 mg/kg, orally for 14 consecutive days), (4) Cisplatin + Bromelain (100 mg/kg, orally for 14 consecutive days). The activity of total antioxidant capacity (TAC) and total oxidant status (TOS) and levels of reactive oxygen species (ROS), superoxide dismutase (SOD), malondialdehyde (MDA), interleukin-1 beta (IL-1 beta), IL-10, nuclear factor kappa B (NF-kappa B), tumor necrosis factor-alpha (TNF-alpha) and 8-OHdG were measured in ocular tissue. The mRNA expression of NF-kappa B and Caspase-3 was also evaluated. Also, ocular sections were evaluated histopathologically. Bromelain demonstrated a dose-dependent protective effect in cisplatin-induced toxicity by regulating oxidative stress, inflammation, and tissue damage. Our results suggested that bromelain may be a potential adjuvant that can protect the eye from cisplatin-induced toxicity.
- Dergi
- DRUG AND CHEMICAL TOXICOLOGY
- Yıl
- 2023
- Cilt
- 46
- Sayı
- 1
- Sayfa
- 69-76
- ISSN
- 0148-0545
- eISSN
- 1525-6014
- DOI
- 10.1080/01480545.2021.2011308
- WoS UID
- WOS:000729677000001